Boston Scientific Announces U.S. FDA Approval for MRI Labeling on High-Voltage Devices and U.S. Launch of Resonate(TM) Devices with the HeartLogic(TM) Heart Failure Diagnostic
MARLBOROUGH, Mass., Sept. 25, 2017 -- (Healthcare Sales & Marketing Network) -- Boston Scientific (NYSE: BSX) has launched the Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) sys... Devices, Cardiology, FDA Boston Scientific, Resonate, ICD , CRT-D, SmartCRT, HeartLogic
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cardiac Resynchronization Therapy | Cardiology | Heart | Heart Failure | Marketing | Pharmaceuticals